Lazard Asset Management LLC Agenus Inc Transaction History

Lazard Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.45 - $2.95 $3,522 - $7,165	-2,429 Reduced 2.89%	81,579 $124,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $3.25 $2.16 Million - $3.47 Million	-1,069,030 Reduced 92.71%	84,008 $201,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.14 $2.1 Million - $3.37 Million	1,071,912 Added 1321.29%	1,153,038 $2.36 Million
Q2 2022 Aug 09, 2022	BUY	$1.3 - $2.64 $105,463 - $214,172	81,126 New	81,126 $157,000
Q1 2022 May 13, 2022	SELL	$2.35 - $3.47 $54,390 - $80,313	-23,145 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$2.92 - $5.74 $115,696 - $227,430	-39,622 Reduced 63.13%	23,145 $74,000
Q3 2021 Nov 15, 2021	BUY	$4.98 - $6.63 $312,579 - $416,145	62,767 New	62,767 $329,000
Q4 2020 Feb 11, 2021	SELL	$3.17 - $4.49 $42,842 - $60,682	-13,515 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$2.98 - $5.2 $40,274 - $70,278	13,515 New	13,515 $54,000
Q1 2020 May 14, 2020	SELL	$1.92 - $4.39 $9,899 - $22,634	-5,156 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$2.41 - $4.4 $12,425 - $22,686	5,156 New	5,156 $20,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.